Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.
about
CSPG4: a prototype oncoantigen for translational immunotherapy studies.T-cell receptor-engineered T cells for cancer treatment: current status and future directions.RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
P2860
Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Combining a chimeric antigen r ...... hit immunotherapy of melanoma.
@en
Combining a chimeric antigen r ...... ssing two additional receptors
@nl
type
label
Combining a chimeric antigen r ...... hit immunotherapy of melanoma.
@en
Combining a chimeric antigen r ...... ssing two additional receptors
@nl
prefLabel
Combining a chimeric antigen r ...... hit immunotherapy of melanoma.
@en
Combining a chimeric antigen r ...... ssing two additional receptors
@nl
P2860
P356
P1476
Combining a chimeric antigen r ...... hit immunotherapy of melanoma.
@en
P2093
Gerold Schuler
P2860
P304
P356
10.1111/EXD.13095
P577
2016-06-01T00:00:00Z